OpenAlex
PricingAboutJobs
Log inGet started
Work

Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor

HTML

Year: 2006
Type: article
Source: Molecular Cancer Therapeutics
DOI: 10.1158/1535-7163.mct-05-0410
Authors: Daniel H. Albert, Paul Tapang, Terrance J. Magoc, Lori J. Pease, David R. Reuter, Ru-Qi Wei, Junling Li, Jun Guo, Peter F. Bousquet, Nayereh S. Ghoreishi-Haack, Baole Wang, Gail T. Bukofzer, Yi-Chun Wang, Jason A. Stavropoulos, Kresna Hartandi, Amanda L. Niquette, Nirupama Soni, Eric F. Johnson, J. Owen McCall, Jennifer J. Bouska, Yanping Luo, Cherrie K. Donawho, Yujia Dai, Patrick A. Marcotte, Keith B. Glaser, Michael R. Michaelides, Steven K. Davidsen
Institution: Abbott (United States)
Language: English

Topic: Angiogenesis and VEGF in Cancer
Subfield: Molecular Biology
Field: Biochemistry, Genetics and Molecular Biology
Domain: Life Sciences
Keywords: ABT-869, VEGF receptor inhibition, PDGF receptor inhibition, KDR, CSF1R, FLT3, antiproliferative activity, apoptosis, angiogenesis inhibition, corneal neovascularization, uterine edema, tumor xenografts, breast cancer, glioma, leukemia, squamous cell carcinoma, fibrosarcoma, small cell lung cancer, colon cancer, combination therapy, pharmacokinetics, plasma protein binding
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W922724308
FWCI: 3.98
Cites: 65
Cited by: 217
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms